INDIVIDUAL TEST 930
C3d
Indication
Suspicion of inflammatory disorders with complement activation
Sample material
EDTA-plasma
- Minim. volume: 0,5 mL
Transport
- Within Sweden: frozen
- International: frozen
Method
Nephelometry
Reference interval
<5.3 mg/L
Result
Results are reported as normal or elevated with a concentration (mg/L).
Interpretation
C3 and its fragments (C3b, iC3b, C3d) are key in the complement system, driving inflammation and immune regulation. C3d, a stable end-product of C3 degradation, interacts with CR2 to modulate adaptive immunity.
Elevated levels of C3d indicate complement activation with degradation of C3.
References
- Alkaff FF et al. Clin Kidney J. 2025. Alternative pathway-mediated tubular complement activation in human proteinuric kidney diseases: a proof-of-concept study. PMID: 41215783
- Dragon Durey MA et al. Curr Opin Immunol. 2025. Complement in antiphospholipid syndrome, time to target? PMID: 40774121
- Catanese L et al. Int J Mol Sci. 2024. Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review. PMID: 38542491
Last updated: 2025-12-05
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 930
C3d
Indikation
Misstanke om inflammatoriska systemsjukdomar med komplementaktivering
Provmaterial
EDTA-plasma
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: fryst
- Internationellt: fryst
Metod
Nefelometri
Referensintervall
<5.3 mg/L
Resultat
Resultat anges som normalt eller förhöjt med koncentration (mg/L).
Tolkning
C3 och dess fragment (C3b, iC3b, C3d) är centrala komponenter i komplementsystemet där det styr inflammation samt immunreglering. C3d, en stabil slutprodukt av C3-nedbrytning, interagerar med CR2 för att reglera det adaptiva immunsvaret.
Förhöjd nivå C3d talar för komplementaktivering med konsumtion av C3.
Referenser
- Alkaff FF et al. Clin Kidney J. 2025. Alternative pathway-mediated tubular complement activation in human proteinuric kidney diseases: a proof-of-concept study. PMID: 41215783
- Dragon Durey MA et al. Curr Opin Immunol. 2025. Complement in antiphospholipid syndrome, time to target? PMID: 40774121
- Catanese L et al. Int J Mol Sci. 2024. Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review. PMID: 38542491
Senast uppdaterat: 2025-12-05